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Public preferences for prioritizing preventive 
and curative health care interventions:  
a discrete choice experiment 
 
Luyten Jeroen, Kessels Roselinde, Goos Peter & Beutels Philippe 
 
 
Abstract [First-level Header] 
Objective: Setting fair health care priorities counts among the most difficult ethical 
challenges our societies are facing. Through a discrete choice experiment we elicited the 
Belgian adult population’s (18-75y; N = 750) preferences for prioritizing health care and we 
investigated whether these preferences are different for prevention versus cure.  
Methods: We used a Bayesian D-efficient design with partial profiles, which enables 
considering a large number of attributes and interaction effects. We included the attributes 1) 
type of intervention (cure versus prevention); 2) effectiveness; 3) risk of adverse effects; 4) 
severity of illness; 5) link between the illness and patient’s health-related lifestyle; 6) 
timespan between intervention and effect, and 7) patient’s age group.  
Results: All attributes were statistically significant contributors to the social value of a health 
care program, with patient’s lifestyle and age being the most influential ones. Interaction 
effects were found, showing that prevention was preferred to cure for disease in young adults, 
as well as for severe and lethal disease in people of any age. However, substantial differences 
were found in the preferences of respondents from different age groups, with different 
lifestyles and different health states. 
Conclusion: Our study suggests that, according to the Belgian public, contextual factors of 
health gains like patient’s age and health-related lifestyle should be considered in priority 
setting decisions. The studies, however, also revealed substantial disagreement in opinion 
between different population subgroups.  
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Introduction [First-level Header] 
One of the greatest challenges for the future consists in finding a fair match between ever-
increasing medical needs and possibilities on the one hand, and finite health care budgets on 
the other. Consensus exists that such priority setting should reflect a concern for both 
efficiency (making maximal use of valuable resources) and equity (avoiding that some people 
become deprived of their deserved share) (1,2). Over the past decades, the concern for 
efficiency has been operationalized in cost-utility analysis (CUA), informing decision makers 
on the ratio between incremental costs and incremental Quality-Adjusted Life Years 
(QALYs) attributable to interventions (3). Equity, however, remains a much more elusive 
concept as a large number of contextual considerations of patients, illnesses or interventions 
could justify a more or less favorable weighing in rationing decisions (4). Therefore, an 
important research objective remains to clarify which distributive principles carry social 
support.  
The aim of this paper is to contribute to the empirical literature describing the general public’s 
distributive preferences regarding health care. We do so by means of a discrete choice 
experiment (DCE) held in a representative sample of the Belgian adult population. We pay 
specific attention to the following two issues. First, published studies about preferences for 
health care resource allocation largely ignored the difference in nature between prevention 
and cure. Unlike cure, however, prevention: 1) avoids the intangible costs of experiencing ill-
health 2) can give rise to substantial externalities, with consequences for both efficiency and 
equity (5) (e.g. herd immunity through vaccination (6); 3) is closely related to social justice 
(e.g. by adjusting social determinants of health) (7); and 4) is only attributed a small fraction 
(< 5%) of the health care budget in most countries (8), and may be first to be cut in times of 
scarcity. In this study, we pay specific attention to the relative value of either type of health 
care and investigate whether their nature affects rationing principles. Second, an important 
criticism against studies eliciting social preferences is that aggregation covers up important 
heterogeneity in the ethical views of different respondents (7). We therefore pay much 
attention to differences in the preferences of relevant subgroups, via the inclusion of several 
respondent characteristics as covariates in our analysis. 
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Methods [First-level Header] 
Discrete choice experiments (DCEs) are a widely used technique to quantify individuals’ 
preferences by observing their stated choices in a number of hypothetical scenarios (9-11). 
Respondents are confronted with a sequence of choice sets consisting of two or more 
competing options. For each choice set they have to indicate the option they like best. The 
options are described in terms of a fixed set of attributes or dimensions that differ in their 
levels. The data from a DCE allow the assessment of the relative importance of each attribute 
in the total value attributed to the options under valuation.  
DCEs are predominantly used to elicit personal preferences (for a general review of 
applications, see 12), but, in a number of studies, they have also been used to explore a 
population’s social and ethical views regarding priority setting in health care (e.g. 13, 14; for 
specific reviews, see 15-17). One motivation for using DCEs in the latter context is that 
respondents are forced to consider the consequences of their choice (choosing for one option 
implies foregoing of the other), which avoids that they simply ignore the fact that health care 
resources are limited. 
Conducting a DCE involves the following steps: 1) identification of the attributes and 
attribute levels; 2) experimental design of the choice sets; 3) survey development; 4) sample 
selection and survey administration; and 5) data analysis.  
Identification of the attributes and attribute levels [Second-level Header] 
For our research objective, it was important to identify a number of decontextualized, generic 
characteristics that provide a workable description of both preventive and curative 
interventions. These characteristics should enable respondents to make a meaningful 
judgment regarding the necessity to reimburse a given intervention. We considered literature 
review and expert opinion the preferable sources of information. Reviews have classified 
considerations, potentially relevant for rationing health care programmes, in three groups: 
characteristics belonging to the patient, the intervention and the health condition (15,18). We 
updated a review of DCEs about priority setting (17) and identified 12 DCEs exploring the 
social value of health care (13, 14, 17, 19-27). We reviewed these studies focusing on the 
attributes used. We observed that all studies used combinations of attributes to indicate what 
would happen when a patient would not receive care (severity of illness, expressed in 
morbidity and/or mortality), and what would happen in case a patient received care 
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(effectiveness of the intervention/health improvement). Additionally, the studies involved a 
cost or budget impact attribute, the number of patients affected, alternative treatment options 
and characteristics of the recipient (mainly age or health-related lifestyle). 
The reviewed studies, however, mainly focused on cure, either explicitly or implicitly by 
shaping a context that is intuitively associated with curing patients, rather than with 
preventing illness. Therefore, we carried out a separate review of studies aiming to elicit 
preferences for prevention in order to find additional attributes. In a review of 114 DCEs (12), 
we found nine specifically applied to preventive interventions such as screening tests or 
vaccines (28-36) These nine studies suggested the inclusion of two additional attributes in our 
DCE, namely the intervention’s risk on adverse effects and the timespan between the 
intervention and its clinical effect.  
In sum, our literature review suggests the following list of nine attributes as most useful to 
include in our DCE: type of intervention (curative or preventive), effectiveness of the 
intervention, adverse effects associated with the intervention, severity of illness, cost of the 
intervention, number of patients, relation to health-related lifestyle, timespan between the 
intervention and the expected effect and age group of the patient.  
Subsequently, we organized group discussions with convenience samples consisting of 
researchers (N = 10) and lay persons (N = 14) in which we presented interventions in terms of 
these nine characteristics to investigate whether we overlooked potentially important 
attributes and whether the descriptions we used for the attributes and their levels allowed a 
realistic mental image of a health care program. No additional attributes were considered 
essential. However, when we tested exploratory choice sets, it appeared that inclusion of all 
nine attributes made the cognitive burden too large for respondents. Respondents not only had 
to compare the characteristics of the intervention and the disease, but they also had to 
consider scale differences between both programs (cost and number of patients). This extra 
dimension required respondents to make calculations and made them raise questions for 
clarification. Therefore, we decided to exclude the attributes cost and number of patients by 
mentioning in every choice set that the interventions had the same cost and were beneficial 
for the same number of patients. 
The next challenge was to refine the wording used to describe the attributes and their levels, 
and to consider other than verbal presentations of the attribute levels. First, we presented all 
attributes to our convenience sample in various formulations to determine which one was 
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easiest to understand. Since the use of attributes representing risks or chances is cognitively 
demanding, we considered using visualizations for the levels of the attributes effectiveness, 
risk on adverse effects and lifestyle instead of verbal descriptions (37). However, we learnt 
that a verbal description was most reliable, because it minimized the cognitive burden 
imposed on the respondents while still bringing across the intended meaning. Also for the 
other attributes, we experimented by describing levels using numbers and percentages, and 
found that the choice task was most intuitive when we described levels verbally. Terms such 
as ‘rarely’ and ‘often’ are more judgmental than numbers and chances (e.g. 1 adverse effect 
per 100 interventions) and they may translate into different numerical equivalents in different 
respondents. Using probabilities, however, does not guarantee equal interpretation (e.g. is a 
chance of 1 per 100 rare or often?). As for our purpose the qualitative rather than quantitative 
judgment of the respondent was what mattered, we opted for qualitative descriptions for a 
limited number of attribute levels.  
We utilized three levels for each attribute, except for the attributes type of intervention, which 
has two levels, and age group of the patient, which has five levels. For the age attribute, we 
decided against covering all ages because this would make the age groups very wide. Instead 
we opted for equally wide age intervals at different stages of life. Table 1 shows the 
descriptions of the attributes and their levels used. We presented the attributes one by one to 
the members of our convenience sample and asked them how they interpreted each attribute 
and attribute level. We encountered no difficulties in understanding.   
Table 1: Attributes and levels. 
Attribute Level 
What type of intervention is it? 
1. preventive (aiming to prevent healthy persons from becoming ill) 
2. curative (aiming to cure people who are ill) 
How big is the probability of 
success of the intervention? 
1. 1 in 3 is successful (33%) 
2. 2 in 3 is successful (66%) 
3. always successful (100%) 
How often do adverse effects 
occur? 
1. often 
2. rarely 
3. never 
How severe is the illness for 
which the intervention is 
developed? 
1. not lethal, but everyone who gets the disease will experience a short 
period of illness without lasting effects (not severe) 
2. not lethal, but everyone who gets the disease will experience a severe 
and lasting reduction in quality of life (severe) 
3. lethal, everyone who gets the disease will die from it (lethal) 
Does the patient cause the disease 
through his or her own lifestyle? 
1. fully 
2. partly 
3. not at all 
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How long does it take before the 
patient becomes ill/ shows 
signs/symptoms of illness? 
1. after 20 years 
2. after 5 years  
3. within a year 
At what age does the patient 
become ill? 
1. 80 – 90 years 
2. 60 – 70 years 
3. 40 – 50 years 
4. 20 – 30 years 
5. 0 – 10 years 
 
Experimental design of the choice sets [Second-level Header] 
The DCE presented respondents with 14 choice sets of two competing medical interventions, 
termed ‘profiles’ henceforth. The profiles are combinations of levels of the seven attributes in 
Table 1. To limit the cognitive burden imposed on the respondents, we used ‘partial profiles’ 
(38-40), i.e. we varied the levels of only four of the seven attributes in the choice sets and 
kept the levels of the other attributes constant. However, different attributes are held constant 
across choice sets at levels that change between choice sets. We did show the constant 
attributes to the respondents. This improves the validity of the parameter estimates on the one 
hand (41), and allows for the estimation of interaction effects on the other hand. To facilitate 
the choice tasks, we highlighted the varying attributes in each choice set. Figure 1 shows an 
example choice set where respondents had to choose between two interventions A and B. 
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To maximize the information content of the DCE, we created three different surveys by 
constructing a partial profile design involving 42 choice sets and dividing it into three groups 
of 14 choice sets such that each group or survey has a similar partial profile design structure 
(see below). In constructing the design profiles, we excluded four unrealistic combinations of 
levels of two attributes [shown in Appendix A in Supplemental Materials at: XXX (which 
also includes the three surveys)]. We ensured that each survey was filled out an equal number 
of times. As pointed out by Sándor and Wedel (74), using 42 instead of 14 different choice 
sets results in a larger amount of information on the respondents’ preferences and therefore in 
more precise estimates of the relative importance of the attributes and attribute levels.  
Besides the estimation of the main effects of the attributes, we were also interested in 
estimating the interactions between ‘type of intervention’ and any other attribute. However, 
because of the disallowed level combinations associated with the attribute ‘timespan’ (shown 
in Appendix A in Supplemental Materials at: XXX), the interaction between ‘type of 
intervention’ and ‘timespan’ cannot be estimated. As a discrete choice model, we used a 
multinomial logit (MNL) model, which is common practice in discrete choice design and 
analysis (10). The partial profile design in Appendix A (in Supplemental Materials at: 
XXX) is D-efficient or D-optimal for the MNL model, meaning that it guarantees precise 
estimates of the main effects and the interactions between ‘type of intervention’ and five other 
attributes (43).  
Each choice set of the D-efficient partial profile design varies the levels of four of the seven 
attributes. These varying attributes differ from choice set to choice set. We determined them 
using the attribute balance approach that attempts to vary each attribute in an equal number of 
choice sets and to pair varying attributes an equal number of times (39, 40). That is why each 
attribute is varied in eight choice sets of each survey of the partial profile design.  
The D-efficient partial profile design takes into account prior knowledge concerning the 
respondents’ preferences. For our DCE, for example, it generally holds that the expected 
priority ranking for reimbursement of interventions is, from low to high, related to a mild 
disease, followed by a severe, but not lethal disease, and finally, a lethal disease. Similarly, 
for all other attributes, we took into account expert prior information about the most logical 
ordering of the levels of the attributes, from low priority to high priority, the result of which is 
shown in Table 1. We also ranked the attributes in order of expected importance and 
expressed our uncertainty regarding the a priori orderings of the attributes and attribute levels 
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in a multivariate normal prior distribution. In Appendix B (in Supplemental Materials at: 
XXX), we discuss in detail how we obtained that multivariate normal prior distribution to 
optimize the design. The design that maximizes the information content of the DCE [as 
measured by the log-determinant of the information matrix; see (43)], when averaged over 
that prior distribution, is called a Bayesian D-efficient design. The Bayesian D-efficient 
design approach is increasingly considered a state of the art approach for DCEs (see, e.g., 43-
47, see also Appendix C in Supplemental Materials at: XXX). Major benefits of Bayesian 
D-efficient designs are that, using a proper prior distribution, they avoid choice sets in which 
one profile is completely dominating the other profile(s) on every attribute (48), and (as 
demonstrated below) such designs can be constructed to efficiently estimate interaction 
effects. 
Survey development  [Second-level Header] 
We provided respondents with a web link that allowed them to carry out the choice tasks at 
their earliest convenience. To help respondents, we presented a thorough explanation of the 
choice tasks at the beginning of the DCE to familiarize them with 1) the context of increasing 
scarcity in health care, the problem of setting fair priorities and our objective to investigate 
how the general population thinks about this difficult ethical policy issue, and 2) all seven 
attributes and their levels and how they are used in the description of a treatment or a 
preventive intervention. We asked respondents to choose between two interventions of which 
only one could be reimbursed by the government.  
After the DCE, we asked respondents a number of background questions concerning their 
age, gender, height, weight, educational attainment, family size, experience as health care 
worker (HCW), smoking status and experience with severe illness (personal or within the 
family). In order to have an estimate of the respondent’s current health state, the respondents 
also had to complete the EuroQol health survey (i.e. the Visual Analogue Scale (VAS) and 
the generic EQ-5D-5L) (49, 50). These are all variables that we a priori considered to be of 
potential relevance to someone’s health care preferences. 
Sample selection and survey administration [Second-level Header] 
In June 2012 a sample was drawn, representative of the Belgian population in terms of age, 
gender, region and educational attainment, from an actively managed, continuously updated 
panel of 10,753 Belgians. Participation was incentivized with credits by means of which, after 
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a number of positively evaluated survey participations, gifts could be bought and a lottery 
organized on a per survey basis. Only one respondent per household was allowed. The market 
research company guarantees high-quality data through checks and ensures that only ‘serious’ 
respondents are included. To this end, fraudulent, inattentive, hyperactive or conditioned 
respondents were removed from the sample, e.g. respondents who complete the survey 
unreasonably fast (‘speedsters’), consistently give the same answer (‘straightliners’), etc. 
A total of 30% (N = 3,160) of the 10,753 contacted individuals agreed to participate, of which 
937 were selected based on the quota requirements. Of the selected individuals, 149 did not 
finish the survey and 38 did not meet the quality criteria. This left us with a sample of 750 
respondents (250 respondents for each of the three versions of the survey), and 10,500 
observed choices in total, i.e. 14 per respondent. Respondents were distributed proportionally 
over the three survey versions according to language, gender and age. Table 2 compares basic 
characteristics of the sample to those of the population, showing overall good agreement. 
Given the societal context of this study, and a lack of clarity about the criteria (additional to 
the ones described in the previous paragraph) that can identify irrational response data in a 
DCE without imposing preferences (51, 52), all 750 respondents were included in our 
analysis. 
 
Table 2: Sample characteristics relative to those of the Belgian population. 
 Sample Belgian population 
Language   
Dutch 56% 56% 
French 44% 44% 
Gender   
Male (M) 50% 50% 
Female (F) 50% 50% 
Gender per age group †   
18 – 25 M 6% 6% 
18 – 25 F 6% 6% 
25 – 34 M 9% 9% 
25 – 34 F 10% 9% 
35 – 44 M 10% 11% 
35 – 44 F 10% 10% 
45 – 54 M 10% 10% 
45 – 54 F 11% 10% 
55 – 64 M 9% 8% 
55 – 64 F 10% 8% 
65 – 74 M 6% 6% 
65 – 74 F 4% 6% 
Level of education *   
None or lower education 8% 19% 
Lower secondary 
education 
10% 20% 
Higher secondary 
education 
31% 33% 
Higher non-university 
education 
35% 18% 
University  15% 10% 
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Province   
Antwerp 15% 16% 
West Flanders 10% 11% 
East Flanders 13% 13% 
Limburg 8% 8% 
Hainault 13% 12% 
Liege 10% 10% 
Luxemburg 3% 2% 
Namur 5% 4% 
Brussels  10% 10% 
Flemish Brabant 11% 10% 
Walloon Brabant 3% 3% 
Smoking status 
‡
   
Never smoked 45% 54% 
Ex-smoker 30% 22% 
Smoker 25% 25% 
 
Source Belgian Data:   Federale Overheidsdienst Economie (70) 
† Age: The percentages reported are proportions in the selected population (18-75), representing 71% of the total 
Belgian population.  
* Education: The percentages reported for the Belgian population are for the age group 15 years or older. The 
percentages for our sample are only for the age group 18-75 years. The overrepresentation of higher educated 
respondents in our sample as compared to the total population can be explained by our exclusion of the group 
15-18 years that is too young for higher education, and the age group 75 years or older for which higher 
education was less democratically accessible.   
‡ Smoking percentages from the population are based upon the following study (71) and are representative for 
the population aged 15 years or older. 
 
2.5 Data analysis [Second-level Header] 
The data we collected through our DCE allow quantification of and statistical inference about 
the relative importance of the attributes and attribute levels in assessing the priority ranking of 
a health intervention. This is done by estimating the respondents’ utility function as part of the 
multinomial logit (MNL) model, using a maximum likelihood approach. The utility function 
is represented by the sum of the utilities of the attributes’ main and interaction effects under 
study. The overall significance of the attributes was computed using likelihood ratio (LR) 
tests and the relative importance of the attributes was measured by –log (p-value of the LR 
test). We started our analysis by estimating the a priori MNL model, i.e. the model that 
seemed most useful when planning the entire study and which was used as a basis for 
constructing the D-efficient design for the DCE. That model includes the main effects of all 
attributes and the interactions between type of intervention and five other attributes. Next, we 
dropped the insignificant model terms until we obtained a final model in which all remaining 
effects had significant explanatory value. Preference heterogeneity (section 3.2) was assessed 
- in a separate analysis - by adding an interaction term in the model with a variable that we a 
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priori determined to be of potential interest (e.g. gender or respondent’s age). We carried out 
the entire data analysis using the Choice Modeling platform in the statistical software package 
JMP 10.  
Results [First-level Header] 
Main and interaction effects [Second-level Header] 
Figure 2 and Table 3 summarize the results of our analysis. All 7 attributes are statistically 
significant contributors to the social value of a health care intervention, meaning that none of 
them is considered irrelevant to priority setting. As shown in Figure 2, the most influential 
attributes (based on the LR test) are the patient’s health-related lifestyle and age. They are 
about twice as important as the intervention’s effectiveness and about four times as important 
as severity of illness. Type of intervention is also an important attribute for the model because 
it appears in two significant interaction effects: between ‘type of intervention’ and ‘patient’s 
age’ and between ‘type of intervention’ and ‘severity of illness’ (see below). Its importance is 
shown by the LR test for the joint significance of the three effects involving this attribute (LR 
Chi-square = 26.19; DF = 7; p-value = 0.0005). Timespan is the attribute that is least 
important.  
Figure 2: Importance of the 7 attributes (main and interaction effects) to the social value of a 
health care program relative to the most important attribute ‘lifestyle of patient’, the 
importance of which is set to 100. 
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The main-effect estimates in Table 3 represent the utilities attached to the different levels of  
the attributes. The direction of the coefficients across the levels of each attribute is in line 
with our a priori expectations. The attractiveness for reimbursement increased as the 
intervention was more effective or had a lower risk of adverse effects, when the disease was 
more severe or occurred earlier in time and when the patient’s age and the link between the 
disease and the patient’s lifestyle was lower. Figure 4 visualizes this for the two most 
influential attributes: patient’s age and link with patient’s lifestyle (for the total sample and 
for specific subgroups, see section 3.2). Looking at the 95% confidence intervals for the 
utility estimates of each level we judge that most coefficients are different on a statistically 
significant level. In a few cases the level estimates did not significantly differ: the adverse 
effects levels ‘never’ and ‘rarely’, the patient’s age levels ‘0-10 years’ and ‘20-30 years’ and 
the timing levels ‘within a year’ and ‘after 5 years’. 
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Table 3: Estimates of coefficients in the MNL model, their 95% confidence intervals (CIs) 
and overall significances of the attributes using p-values obtained from likelihood ratio tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Term Estimate 95% CI P-value 
Lifestyle of Patient    
fully -0.3742 -0.4324; -0.3163 
<0.0001 partly 0.0483 0.0046; 0.0921 
not at all  0.3259
*
 0.2685; 0.3833 
Age of Patient    
80 – 90 years -0.6160 -0.7088; -0.5241 
<0.0001 
60 – 70 years -0.0067 -0.0829; 0.0695 
40 – 50 years 0.1168 0.0479; 0.1857 
20 – 30 years 0.2206 0.1485; 0.2929 
0 – 10 years  0.2853
*
 0.2012 ; 0.3694 
Effectiveness    
33% -0.2584 -0.3171; -0.2001 
<0.0001 66% 0.0282 -0.0177; 0.0741 
100%  0.2302
*
 0.1765; 0.2840 
Severity of Illness    
not severe -0.2210 -0.2946; -0.1476 
<0.0001 severe 0.0653 0.0245; 0.1061 
lethal  0.1557
*
 0.0812; 0.2303 
Adverse Effects    
often -0.1582 -0.2131; -0.1037 
<0.0001 rarely 0.0856 0.0426; 0.1287 
never  0.0726
*
 0.0235; 0.1221 
Type*Age of Patient    
preventive*80 – 90 years 0.0120 -0.0397; 0.0638 
0.0005 
preventive*60 – 70 years -0.0676 -0.1190; -0.0162 
preventive*40 – 50 years -0.0480 -0.1038; 0.0078 
preventive*20 – 30 years 0.1103 0.0537; 0.1669 
preventive*0 – 10 years -0.0067
*
 -0.0732; 0.0600 
curative*80 – 90 years -0.0120
*
 -0.0638; 0.0397 
curative*60 – 70 years  0.0676
*
 0.0162; 0.1190 
curative*40 – 50 years  0.0480
*
 -0.0078; 0.1038 
curative*20 – 30 years -0.1103
*
 -0.1669; -0.0537 
curative*0 – 10 years  0.0067
*
 -0.0600; 0.0732 
Timespan    
after 20 years -0.0843 -0.1529; -0.0155 
0.0404 after 5 years 0.0234 -0.0273; 0.0741 
within a year  0.0609
*
 0.0069; 0.1148 
Type*Severity of Illness    
preventive*not severe -0.0431 -0.0801; -0.0059 
0.0487 
preventive*severe 0.0345 -0.0041; 0.0731 
preventive*lethal  0.0086
*
 -0.0330; 0.0503 
curative*not severe  0.0431
*
 0.0059; 0.0801 
curative*severe -0.0345
*
 -0.0731; 0.0041 
curative*lethal          -0.0086
*
 -0.0503; 0.0330 
Type    
preventive 0.0137 -0.0297; 0.0571 
0.5376 
curative  -0.0137
*
 -0.0571; 0.0297 
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*Coefficient estimates corresponding to the last level of an attribute, either as main effect or 
involved in an interaction, are indicated in italic to stress that they are calculated as minus the 
sum of the estimates for the other levels of that attribute. To illustrate, the value of 0.0086 for 
the interaction effect Type[preventive]*Severity of illness[lethal] is obtained as –(–
0.0431+0.0345). 
 
In Figure 3 the two interactions involving type of intervention are plotted. Our data suggest 
that the relative value of cure versus prevention differed as a function of the age group of the 
patient and the severity of the health problem. As shown in Panel A, however, the interaction 
with age is mainly due to the upward kink at 20-30 years in the value of prevention and the 
downward kink at the same age category in cure. For patients older than 30, the utility of 
prevention declined, whereas the value of cure remained relatively stable over the age interval 
from 20 to 70. However, we judge that this difference in utility between prevention and cure 
in older age groups is statistically not significant, since from the 95% confidence intervals we 
observe that the interaction effects type[preventive]*age of patient[40-50 years] and 
type[preventive]*age of patient[60-70 years] belong to each other’s confidence interval. 
Regarding the second interaction, Figure 3’s Panel B shows that severity of illness had a 
larger impact on the utility of a preventive intervention than on that of a curative one. 
Prevention was valued less than cure in case of a non-severe, transient illness. However, it 
was valued more for severe long-lasting and life-threatening diseases. Our respondents did 
not consider effectiveness, risk of adverse effects or lifestyle to be of differential importance 
in choosing between prevention and cure (i.e. these attributes did not interact with type of 
intervention).  
 
Figure 3: Marginal utility values for different combinations of “Age of Patient” and “Type of 
Intervention” (Panel A) and for different combinations of “Severity of Illness” and “Type of 
Intervention” (Panel B). 
A.           B. 
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Preference heterogeneity [Second-level Header] 
We found many differences in the preferences of various subgroups (indicated by a 
statistically significant interaction effect). The largest interactions (based on the LR test) were 
found between respondent’s age and patient’s age, and between respondent’s smoking status 
and patient’s lifestyle.  
Respondent’s age [Third-level Header] 
Younger respondents attributed significantly more importance to patient’s age (p < 0.001), 
severity of illness (p < 0.001) and patient’s lifestyle (p = 0.0001). To visualize the impact of 
the respondent’s age, we partitioned the respondents of our dataset in three age groups: 18-
35y, 36-60y and 61-75y (see Fig. 4). For the youngest respondents, the social value of an 
intervention depended more strongly on the patient’s age (Panel A, dotted line) and the link 
between the disease and the patient’s lifestyle (Panel B, dotted line) than for the older 
respondents.  
Gender [Third-level Header] 
The covariate gender appeared in two significant interactions, one involving the attribute 
patient’s age (p = 0.003) and one involving the attribute effectiveness (p = 0.01). Female 
respondents attached less value to interventions for older patients than male respondents. 
Male respondents attributed a higher value to effectiveness.  
Level of education and experience in health care [Third-level Header] 
Respondents with a degree of higher education (university or non-university) were more 
willing to ration based on age (p < 0.001), and attribute more importance to severity of illness 
(p < 0.0001). In addition they attributed more value to prevention (p = 0.02). No differences 
in opinion were found between higher and lower educated respondents for the attributes 
lifestyle, effectiveness and adverse effects. Present or past experience as health care worker 
(14% of the sample) did not result in significant interactions.  
Household [Third-level Header] 
The larger the household of the respondent, the more prevention was preferred to cure (p = 
0.003) and the more the value of health care decreased as a function of patient’s age (p = 
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0.002). Respondents living with children gave more importance to patient’s age. No 
significant interactions were found with other attributes.  
Health state [Third-level Header] 
We found significant interactions with the respondent’s VAS and EQ-5D-5L scores. The 
lower the VAS score, the lower the importance of the patient’s age group (p < 0.0001) and the 
stronger the preference for cure over prevention (p < 0.008). The lower their EQ-5D-5L score, 
the more likely respondents were to prefer cure over prevention (p < 0.006) and to prefer 
current health gains over future ones (p < 0.01). Respondents who reported having had 
personal experience with severe illness attached greater value to cure than to prevention (p < 
0.002), and to current rather than to future health gains (p < 0.01). They attributed less 
importance to adverse effects (p < 0.04) and are less inclined to take the age of patients into 
account (p < 0.006). We also partitioned our sample in a ‘good health’ group (74% of the 
sample) and a group with ‘present or past health problems’ (26%), depending on whether or 
not they had personal experience with severe illness, or had an EQ-5D-5L score below 0.6 or 
a VAS score below 60. Both groups differ in that the ‘good health’ group preferred prevention 
(p < 0.002), discounted future health gains to a lesser extent (p = 0.04) and was more willing 
to ration based on age (p = 0.01). Respondents’ choices did not differ significantly based on 
experience with severe illness in their family.  
Lifestyle [Third-level Header] 
Whether or not the respondent is a smoker is a highly influential covariate and, hence, an 
important factor explaining preference heterogeneity among the respondents. Smokers clearly 
attributed a lower importance to the attributes lifestyle (p < 0.0001) and patient’s age (p = 
0.0008), preferred cure to prevention (p < 0.0001), and discounted future health gains to a 
greater extent (p = 0.04). Also, Body Mass Index (BMI) turns out to be an important 
covariate. The higher the BMI score, the less a respondent takes into account the patient’s age 
(p < 0.0032), severity of illness (p = 0.0006) and the disease’s link with lifestyle (p = 0.04) 
and the more (s)he prefers cure to prevention (p = 0.0034) and discounts future health gains (p 
= 0.008). To visualize the differential valuation by respondents with a ‘healthy’ lifestyle and 
patients with an ‘unhealthy’ lifestyle, we partitioned the respondents in two groups, one group 
(in total 38% of the sample) containing respondents with a BMI exceeding 30 [i.e. the obesity 
threshold (53)] as well as smokers and one group containing non-smokers that have a BMI 
lower than 30. The ‘unhealthy’ lifestyle group preferred cure to prevention (p < 0.0001), 
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attributed a lower weight to lifestyle (p < 0.0001) and patient’s age (p < 0.0001) (as illustrated 
in Fig. 4’s Panel B), and, remarkably, attached more importance to the risk of adverse effects 
(p = 0.02).  
Figure 4: Marginal utility values for the attributes “Age of Patient” (Panel A) and “Lifestyle 
of Patient” (Panel B) for the entire sample (general population) and for different respondent 
subgroups [respondents aged 18-35 years, aged 60-75 years and a group defined as having an 
‘unhealthy’ lifestyle (i.e. being smoker or obese)]. 
A.       B. 
 
 
Discussion [First-level Header] 
The objective of our study was to investigate on which basis the Belgian population wants to 
set health care priorities. Although characteristics of the intervention (effectiveness and risk 
of adverse effects) and of the illness (severity of illness and timespan) were found to matter, it 
was mainly the characteristics of the recipient that drove respondents’ preferences. Priority 
was given to younger patients and to those who have not somehow caused their own illness. 
We also detected substantial heterogeneity in the preferences: young, healthy, highly educated 
or more health-conscious adults responded in a markedly different way than older, unhealthy, 
less well educated and health-unconscious ones.  
Our results confirm studies in other countries indicating that the context shapes the social 
value of QALYs, and that the general public’s distributive preferences diverge from a simple 
health maximization approach, as would be prescribed by CUA (i.e. minimizing cost/QALY) 
(e.g. 13, 14, 16, 17, 19, 20, 54;, 24, 25,  ; for reviews see 15, 16 or 55). Many of these studies 
also observe a public preference for prioritizing younger patients over older ones and several 
ones describe how a substantial number of participants want to account for self-inflicted 
illness. However, our results seem to diverge from these other studies in the strong impact of 
the lifestyle attribute, and the relatively limited impact of severity of illness to priority setting. 
18 
 
We paid specific attention to the difference between prevention and cure. A few studies in the 
literature also compared stated preferences for both types of health care (24, 56-60, 69). These 
studies found no preference (56, 57), a preference for prevention (24, 59-60) or a preference 
for cure (58, 69). Our sample valued prevention higher than cure only when it is targeted at 
relatively young age groups and when it protects against more severe illness. However, as the 
self-inflicted nature of a health condition was a factor of major relevance in our study, 
indirectly, our results can also be interpreted as providing further support for prevention in 
general. An allocation scheme that accounts for individual responsibility would mainly ration 
on curative treatments as accountability for lifestyle is less relevant for (not) providing 
prevention, especially when it comes to primary prevention. Preventive programs can 
incentivize, or even enable citizens to adopt healthy and responsible lifestyles before their 
lifestyle-associated risk-exposure requires cure. Currently, preventive “lifestyle” policies such 
as alcohol, fat, sugar or smoking taxes are gaining interest (61, 62). Such measures, if 
effective, would increase short-term government income and reduce lifestyle-related 
morbidity.  
 
Some limitations of our study must be mentioned. First and foremost, priority setting in health 
care requires societal support (63). But the majority is not necessarily right (64, 65). We 
observed that the support for age-based rationing and accounting for lifestyle depends on the 
age and lifestyle of the respondents themselves, indicating some degree of self-serving 
answers. Whereas we conveyed to respondents to answer as citizens (a societal view) and not 
as potential health care consumers (an individual view), and whereas self-serving answers are 
not necessarily unjust, this does raise suspicion of partiality. How this can be avoided, and 
how we can construct a more effective ‘veil of ignorance’ in social preference studies, 
remains a challenge for further research. But even with impartial answers, age-based rationing 
and accounting for lifestyle remain controversial grounds for setting priorities (for an 
elaborate discussion, see 66). The results of public opinion research in this area should always 
be complemented by ethical considerations. Therefore, instead of being directly useful to 
priority-setting decisions, our survey in the first place supports the need for a more extensive 
public debate about the appropriate role of age and lifestyle in health care rationing. 
Second, although our sample was broadly representative of the Belgian population, 
respondents were recruited from an online panel. This excluded respondents older than 75 
years and membership of the panel may be associated with unobservable characteristics. 
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Third, we surveyed our sample on a complex topic, in a single recording. We encouraged 
respondents to think thoroughly about their answer and evidence suggests that respondents’ 
answers to DCEs like ours are reliable (21). Nonetheless, it would be interesting to repeat this 
study in a non-panel sample (e.g. generated through random digit dialing of telephone 
numbers), and to organize a follow-up study in the same sample to compare the results. 
Fourth, an inherent limitation of DCEs is that only a limited number of attributes can be used. 
Although we included a relatively large number of attributes, the choice alternatives we 
presented remain simplified versions of real health care programs. Fifth, because this 
simplified the choice tasks, we excluded the cost attribute. A disadvantage of this was that it 
became impossible to quantify willingness to pay for changes in the attributes levels. Such 
inferences, however, were not our primary objective, and, moreover, they have also been 
shown to be less informative than expected on some occasions (67, 68).  
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